{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:33:16Z","timestamp":1773725596004,"version":"3.50.1"},"reference-count":20,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2014,3,21]]},"abstract":"<jats:p>Despite many treatment advances, metastatic breast cancer remains an incurable disease and is the third leading cause of cancer-related deaths in Europe. Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination. Hand\u2013foot syndrome and diarrhoea are the most frequently reported side effects, while capecitabine-related ileitis is very rare. Deficiency of dihydropyrimidine dehydrogenase activity leads to severe toxicities after administration of 5-fluorouracil or its prodrugs. We report two cases of patients with metastatic breast cancer who developed ileitis after treatment with capecitabine. One patient had a DPYD gene abnormality.<\/jats:p>","DOI":"10.1136\/bcr-2014-203647","type":"journal-article","created":{"date-parts":[[2014,4,19]],"date-time":"2014-04-19T09:47:51Z","timestamp":1397900871000},"page":"bcr2014203647","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature"],"prefix":"10.1136","volume":"2014","author":[{"given":"Maha","family":"Mokrim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe G","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Errihani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Piccart-Gebhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,4,19]]},"reference":[{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds232"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-4-325"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.002"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.4","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2006.n.007"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp261"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-90003-20"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.7","unstructured":"Roche Laboratories Inc. Xeloda (capecitabine) tablets prescribing information. (accessed 23 Mar 2006)."},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)01766-3"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.01.005"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.10","doi-asserted-by":"publisher","DOI":"10.1177\/1078155206069242"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0281"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5394.2001.96007.x"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.13","first-page":"A3064","article-title":"Ileitis following capecitabine use","volume":"155","author":"Bouma","year":"2011","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.14","unstructured":"Barton Debora: Ulcerative ileitis secondary to adjuvant capecitabine for colon cancer: a case report. (UICC world Cancer Congress 2006)."},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.15","doi-asserted-by":"crossref","unstructured":"Al-Gahmi, Kerr IG, Zekri JM, et al. Capecitabine-induced terminal ileitis. Ann Saudi Med 2012;32:661\u20132.","DOI":"10.5144\/0256-4947.2012.661"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.16","doi-asserted-by":"crossref","unstructured":"Radwan ileitis secondary to oral capecitabine. Hindawi Publishing Corporation Case Reports in Medicine Volume 2012. doi:10.1155\/2012\/154981 .","DOI":"10.1155\/2012\/154981"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.17","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2004.n.018"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2209"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.19","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2009.n.039"},{"key":"2025042703251225000_2014.apr19_1.bcr2014203647.20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/CCO.0b013e32835ff318","article-title":"Targeted therapies of solid cancers: new options, new challenges","volume":"25","author":"Awada","year":"2013","journal-title":"Curr Opin Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2014-203647","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:25:20Z","timestamp":1745749520000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2014-203647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,19]]},"references-count":20,"alternative-id":["10.1136\/bcr-2014-203647"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2014-203647","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,19]]}}}